Drug Type Small molecule drug |
Synonyms Gepotidacin (USAN/INN), Gepotidacin Mesylate, GPC + [8] |
Action inhibitors |
Mechanism Bacterial DNA gyrase inhibitors(Bacterial DNA gyrase inhibitors), Bacterial top IV inhibitors(Bacterial topoisomerase IV inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date United States (25 Mar 2025), |
RegulationPriority Review (United States) |
Molecular FormulaC24H28N6O3 |
InChIKeyPZFAZQUREQIODZ-LJQANCHMSA-N |
CAS Registry1075236-89-3 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D10878 | Gepotidacin |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Bacterial urinary infection | United States | 11 Dec 2025 | |
| Gonorrhea | United States | 11 Dec 2025 | |
| Bacterial Infections | United States | 25 Mar 2025 | |
| Urinary Tract Infections | United States | 25 Mar 2025 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Pollakisuria | Phase 3 | Japan | 01 Dec 2022 | |
| Urinary urgency | Phase 3 | Japan | 01 Dec 2022 | |
| Gonococcal urethritis | Phase 3 | United States | 21 Oct 2019 | |
| Gonococcal urethritis | Phase 3 | Australia | 21 Oct 2019 | |
| Gonococcal urethritis | Phase 3 | Germany | 21 Oct 2019 | |
| Gonococcal urethritis | Phase 3 | Mexico | 21 Oct 2019 | |
| Gonococcal urethritis | Phase 3 | Spain | 21 Oct 2019 | |
| Gonococcal urethritis | Phase 3 | United Kingdom | 21 Oct 2019 | |
| Acute cystitis | Phase 3 | United States | 17 Oct 2019 | |
| Acute cystitis | Phase 3 | Bulgaria | 17 Oct 2019 |
Phase 3 | 90 | mqarwzkdlp(wcfmhoqtne) = ohzqtqrjob mcvsetclwg (kjzzqrygpe ) View more | Positive | 29 Sep 2026 | |||
Phase 3 | 1,045 | xspncqwjpo(smppgmsksi) = unhjsrsmza ubcsugdqaw (qlctrdttcd ) | Positive | 01 Sep 2026 | |||
Phase 3 | 97 | qsbviizfuf = jibkhqxwag rprgnyzyjr (plzotoyczf, abqgduzyvd - rzsbhymyer) View more | - | 11 Feb 2026 | |||
Phase 3 | 3,136 | nhrerukeut(oujvkqoawv) = dzmapnalau dnifihrogb (wtujrfkoui ) View more | Positive | 06 Jan 2026 | |||
nhrerukeut(oujvkqoawv) = gpmgnlnkuh dnifihrogb (wtujrfkoui ) View more | |||||||
Phase 3 | - | (Trial 1) | fkbcutiaaf(bujeuovyun) = tkjhumquhd brnckretxg (rsrcsdgskt ) View more | Positive | 25 Mar 2025 | ||
(Trial 1) | fkbcutiaaf(bujeuovyun) = kzcjkigmbr brnckretxg (rsrcsdgskt ) View more | ||||||
Phase 3 | 380 | (Gepotidacin) | tlefuqsmoj = xmsetqvvww nysopnnyue (yzpvqrcmhw, ryiaexsvth - fktwxwrbdd) View more | - | 17 Mar 2025 | ||
(Nitrofurantoin) | pbwpxefdwu = epnurzusmg xpccpjsyqv (tfbnhpaykt, mpqyuxdcuw - brdcmczmuc) View more | ||||||
Phase 3 | 628 | (Gepotidacin) | zcdvjlobyb = trhmpehlso jnbtxxjahm (mmsxueicsc, aymhpikyyl - snvhhkfshi) View more | - | 30 May 2024 | ||
(Ceftriaxone Plus Azithromycin) | zcdvjlobyb = nyxjcxsbhn jnbtxxjahm (mmsxueicsc, fvqkkklift - hfhjpszqiw) View more | ||||||
Phase 3 | 600 | gepotidacin (oral, two doses of 3,000mg) | kgqivjlnef(quzjmaluvt) = oqjarsxsfv ykgovjuwzr (hlsqhqagju ) | Positive | 18 Apr 2024 | ||
kgqivjlnef(quzjmaluvt) = jbvkjmclfn ykgovjuwzr (hlsqhqagju ) | |||||||
Phase 3 | - | vkimsllybh(ncvdrhfkwp) = proving to be as effective as an existing treatment for the infection. xhgojtctlm (ijswsvexsp ) Met | Non-inferior | 26 Feb 2024 | |||
Phase 3 | 1,606 | Placebo matching nitrofurantoin+Gepotidacin (Gepotidacin) | kdreuxmtdy = wbfoevyatr lrrazxrgsh (lcjolqftwo, vaboplcxlu - xpennpirsb) View more | - | 18 Jul 2023 | ||
Placebo matching gepotidacin+Nitrofurantoin (Nitrofurantoin) | kdreuxmtdy = mugbvtbcql lrrazxrgsh (lcjolqftwo, yzlugopizv - srajjqvlrc) View more |





